Evaluation of naloxone in laboratory tests predictive of clinical antipsychotic activity

J. B. Malick, Melvin Billingsley, R. K. Kubena, J. M. Goldstein

Research output: Contribution to journalArticle

6 Scopus citations

Abstract

Naloxone, a pure narcotic antagonist, has been claimed to possess antipsychotic activity in man. Naloxone was evaluated in several laboratory tests in rodents that have been routinely used to predict such activity in humans. When compared to both classical (haloperidol) and non-classical (clozapine) antipsychotic reference agents, naloxone's pharmacological profile did not resemble those of the currently available drugs. Thus, on the basis of the present results, it is difficult to predict that naloxone would exhibit antipsychotic activity in a significant segment of schizophrenic patients. If imbalances in endorphins are related to the development of schizophrenia, drastic alterations in current theories on psychosis and in laboratory tests designed to detect antipsychotic activity are required.

Original languageEnglish (US)
Pages (from-to)475-488
Number of pages14
JournalCommunications in Psychopharmacology
Volume1
Issue number5
StatePublished - Dec 1 1977

All Science Journal Classification (ASJC) codes

  • Medicine(all)

Fingerprint Dive into the research topics of 'Evaluation of naloxone in laboratory tests predictive of clinical antipsychotic activity'. Together they form a unique fingerprint.

  • Cite this

    Malick, J. B., Billingsley, M., Kubena, R. K., & Goldstein, J. M. (1977). Evaluation of naloxone in laboratory tests predictive of clinical antipsychotic activity. Communications in Psychopharmacology, 1(5), 475-488.